1 / 44

Inotropes in Cardiothoracic Surgery

Inotropes in Cardiothoracic Surgery. Objectives. Introduction Classification of inotropes Postoperative myocardial dysfunction. Choice of inotrope Indications in specific settings. introduction. What is inotrope ?. Introduction.

nami
Download Presentation

Inotropes in Cardiothoracic Surgery

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Inotropes in Cardiothoracic Surgery

  2. Objectives • Introduction • Classification of inotropes • Postoperative myocardial dysfunction. • Choice of inotrope • Indications in specific settings

  3. introduction

  4. What is inotrope? Introduction • An inotrope is an agent, which increases or decreases the force or energy of muscular contractions . • Positive inotropicagent enhances myocardial contractility so; cardiac output, the amount of blood ejected by the heart with each beat, will also increase.

  5. Why inotropes? Introduction(cont.) • Maintenance of adequate oxygen balance is one of the primary objectives when dealing with patients undergoing cardiac surgery. • Cardiac output is one of the major components of oxygen delivery .

  6. Introduction(cont.) Due to preoperative cardiac lesion and myocardial dysfunction secondary to the events related to cardiac surgery and cardio pulmonary bypass, circulatory support by pharmacological means is frequently required after surgery.

  7. How do inotropes act? Introduction(cont.)

  8. Classification of inotropic agents

  9. Norepinephrine • principal neurotransmitters in the sympathetic nervous system • potent α- adrenoceptor agonist strong vasoconstrictor • norepinephrine stimulates β1-adrenoceptors, increases both heart rate and contractility. • Norepinephrine does not affect β2-adrenoceptors. • Dose : 2-20µg/min(0.04-0.4 µg/kg/min)

  10. Epinephrine • Hormone secreted by the adrenal medulla • Potent α- and β-adrenoceptor agonist. • so a powerful vasoconstrictor, a positive inotrope, and a positive chronotrope. • But, diastolic blood pressure may decrease as a result of vasodilation due to stimulation of β2-adrenoceptor effects. • Dose : 2-20µg/min(0.04-0.4 µg/kg/min)

  11. Dopamine • An endogenous catecholamine • Stimulates both adrenergic and dopaminergic (D1 and D2) receptors. • Low-dose infusion (<5 µg/kg/min) • Intermediate doses (5-10 µg/kg/min) . • Higher doses (>10 µg/kg/min)

  12. Dobutamine • β 1-adrenergic agonist • Had positive inotropic and peripheral vasodilative properties. • As established dobutamine as a first line therapeutic choice in patients with decompensated HF. • Dose : 2.5-10 µg/kg/min

  13. Phosphodiesterase (PDE) inhibitors • Inodilators • postreceptor” mechanism of action • oral administration . • Milrinone. • Dose : 50 µg/kg over 10 min , then 0.375-0.75 µg/kg/min ,max.: 1.13 mg/kg/min.

  14. Levosimendan • It is one of calcium senstizers • It act by increasing the sensitivity of contractile apparatus (especially troponine-T) to intracellular calcium. • Proarrhythmic activity less common. • Induce peripheral, pulmonary and coronary vasodilatation, via ATP-sensitive potassium channels • Dose : is 6 to 12 µg/kg loading dose over 10 minutes followed by 0.05 to 0.2 µg/kg/min as a continuous infusion.

  15. Postoperative myocardial dysfunction

  16. Postoperative myocardial dysfunction Causes: • aortic cross-clamping • inadequate myocardial protection • hypothermia with cardioplegia and topical iced solutions • surgical trauma • activation of the complement cascade by CPB • reperfusion injury • premature or excessive titration of inotropic agents

  17. Recovery pattern of cardiac function: postoperative changes in the systolic myocardial performance after heart surgery in patients undergoing cardiopulmonary bypass (CPB)

  18. Choice of inotrope

  19. Choice of inotrope Guided • The expected need for inotropes • clinical evidence of depressed myocardial function • Empirical drug choice and titration, with careful hemodynamic monitoring

  20. Choice of inotropes(cont.) Ideal positive inotrope?!! Enhance contractility without any significant increase in heart rate preload, afterload, and myocardial oxygen consumption.

  21. Choice of inotropes(cont.) Ideal positive inotrope?!! Enhance the diastolic function

  22. Choice of inotropes(cont.) Ideal positive inotrope?!! Maintain the diastolic coronary perfusion pressure and thus an adequate myocardial blood flow.

  23. Choice of inotropes(cont.) Ideal positive inotrope?!! It finally should have rapid titration times and onset of action and a short half-life

  24. Choice of inotropes(cont.) • Catecholamines are the mainstay of current inotropic treatment • they can be divided into • more potent (epinephrine, isoproterenol, noradrenaline) and • milder (dopamine, dopexamine, dobutamine

  25. Now , what will you choose?

  26. Indications in specific settings • Coronary artery bypass graft surgery: • In most cases, no or only mild inotrope requirement. • inotropes may be needed in case of preexisting ventricular dysfunction or in case of unsuccessful revascularization if the intra-aortic balloon pump alone is not enough.

  27. Indications in specific settings(cont.) • emergency revascularization of acute myocardial infarction, dobutamine and PDE inhibitors. • off-pump coronary artery bypass graft surgery (dopamine, dobutamine)

  28. Indications in specific settings(cont.) • Chronic heart failure : Combination therapy (i.e. a PDE inhibitor administered along with a beta-adrenergic inotrope, dobutamine or epinephrine) may therefore be the treatment of choice in these patients

  29. Indications in specific settings(cont.) • Diastolic dysfunction : No inotropes at all (or inotropes with a better effect on ventricular relaxation, such as PDE inhibitors, if systolic dysfunction coexists)

  30. Indications in specific settings(cont.) • valvularsurgery Moderately severe aortic stenosis, Inotropic support is rarely needed

  31. Indications in specific settings(cont.) Chronic aortic insufficiency Requiring adequate preload and inotropes

  32. Indications in specific settings(cont.) Mitral stenosis, chronic mitral regurgitation Treatment with inotropes is warranted.

  33. Indications in specific settings(cont.) Acute aortic and mitral regurgitation require aggressive inotropic support even preoperatively

  34. Indications in specific settings(cont.) Tricuspid regurgitation Inotropes are beneficial

  35. Indications in specific settings(cont.) • Orthotopic cardiac transplantation: Routine inotropic support includes isoproterenol (to increase the automaticity, inotropism and pulmonary vasodilation) and dopamine (to add further support whilst maintaining the systemic perfusion pressures).

  36. Indications in specific settings(cont.) • Right ventricular dysfunction: • heart transplantation, • lung transplantation • pulmonary thromboendoarterectomy • left ventricular assist device implantation, • inadequate myocardial protection

  37. Successful management Right ventricular afterload maintenance of the aortic blood pressure The contractile strength • inotropes : • dobutamine, • isoproterenol, • epinephrine, • PDE inhibitors pulmonary vasodilators vasoconstrictors

  38. Conclusion

  39. Conclusion • Postoperative myocardial dysfunction is a major concern in the setting of cardiac surgery since it is extremely frequent and is related to a greater morbidity and mortality. • Inotropic drugs are nowadays an important therapeutic tools in the treatment of perioperative heart failure. • Good selection usually guide our outcome.

  40. Any Question?

More Related